Anticoagulants Market Size, Share, and Trends 2026 to 2035

Anticoagulants Market Size and Trends

The anticoagulants market size accounted for USD 39.77 billion in 2025 and is forecasted to hit around USD 92.44 billion by 2035, representing a CAGR of 8.8% from 2026 to 2035. The demand for anticoagulants has increased due to increased cardiovascular health awareness, driving the anticoagulants market. The increased need for better blood thinners is driving demands for innovative anticoagulant therapies.

Anticoagulants Market Key Takeaways

• North America contributed the largest market share in 2025.
• Asia-Pacific is estimated to expand the fastest CAGR between 2026 and 2035.
• By drug category, the novel oral anticoagulants (NOACs) segment has held the largest market share in 2025.
• By drug category, the Heparin and Low Molecular Weight Heparin (LMWH) segment is anticipated to grow at a remarkable CAGR between 2026 and 2035.
• By route of administration, the oral anticoagulants segment generated a major market share in 2025.
• By route of administration, the injectable anticoagulants segment is expected to expand at the fastest CAGR over the projected period.
• By application, the atrial fibrillation/myocardial infarction (heart attack) segment dominated the market in 2025. 
• By application, the Deep Vein Thrombosis (DVT) segment is projected to expand significantly in the forecast period.

Market Overview

The anticoagulants market refers to the global incidence of cardiovascular diseases such as vein thrombosis, pulmonary embolism, and atrial fibrillation, and medicines and therapies utilized to prevent these disorders. The market has witnessed transforming growth, driven by increased cardiovascular disease prevalence, an aging population, and improved healthcare infrastructure. Drawing focus on the development of innovative and advanced enterprises positively influencing the market. For instance, the adoption of novel oral anticoagulants (NOACs) has increased due to their improved educational safety profiles. Developments of new anticoagulants with improved safety and reduced risk of bleeding events and side effects, addressing emerging markets.

The aging population is the key factor contributing to the global anticoagulants market growth. The risk of cardiovascular disease is high among the aging population. Specific conditions like atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE) are more common in older adults. Also, the elderly population faces a high risk of chronic diseases like hypertension, diabetes, and kidney disease, further contributing to an increase in the risk of cardiovascular disease. The ongoing focus of pharmaceutical companies is to develop anticoagulants with more effectiveness and safety profiles for older adults, coupled with reduced risk of bleeding and balancing the advantages of anticoagulation.

Growth Factors and Trends of the Anticoagulants Market

• Prevalence of cardiovascular diseases: the prevalence of cardiovascular diseases such as stroke, pulmonary embolism, and thromboembolism has increased, driving demand for anticoagulant medicines.
• Aging population: Cardiovascular disease prevalence is high among the aging population, contributing to an increased need for anticoagulants.
• Technological advancements: developments of novel oral anticoagulants with more accurate outcome potential for patients with cardiovascular diseases impact the market growth. Additionally, advancements in diagnostic techniques have improved the addiction and diagnosis of this disease.
• Healthcare expenditure: expanding healthcare infrastructure, providing access to novel and advanced anticoagulants, fueling the market expansion.
• Government initiatives: government and regulatory initiatives for the improvement of healthcare, approvals for novel drugs, and investments in research and developments driving innovations in the emerging market.

The Increasing Adoption of Novel Oral Anticoagulants (NOACs), Presents Significant Growth Opportunities to the Anticoagulants Market

The Novel Oral Anticoagulants (NOACs) are an emerging class of anticoagulants, coupled with their improved efficacy and safety profile compared to conventional anticoagulants. Novel oral anticoagulants are convenient and easy to use, making them more popular. These anticoagulants reduce the risk of bleeding and make them ideal in indications of stroke prevention, deep vein thrombosis, and pulmonary embolism. The rising awareness of novel oral anticoagulants among healthcare professionals and patients contributes to increasing adoption. The increased burden of cardiovascular disease and rising focus on developing novel anticoagulants, including NOACs, are expected to open significant growth opportunities for the anticoagulants market to grow.

Bleeding complications Hinder the Adoption of Anticoagulants 

Anticoagulants increase the risk of major bleeding and intracranial hemorrhage, which can cause life-threatening events. Elderly patients or patients with multiple health conditions are at high risk of bleeding complications. The limited availability of reversal agents for the anticoagulants makes it difficult to manage the bleeding events. These bleeding complications reduce the adoption of antibiotics, particularly for elderly patients. However, monitoring of patients on anticoagulants and the development of novel anticoagulants with improved safety profiles can help to reduce the risk of bleeding.

Report Scope of Anticoagulants Market

Segment Outlook 

Anticoagulants Market By Drug Category

The novel oral anticoagulants (NOACs) segment dominated the market in 2025 due to increased demand for safer and more convenient anticoagulants. The increase in the incidence of cardiovascular diseases like atrial fibrillation, deep vein thrombosis, and pulmonary cardiovascular diseases like atrial fibrillation, deep vein thrombosis, and pulmonary embolism have driven demand for novel oral anticoagulants (NOACs).

The Heparin and Low Molecular Weight Heparin (LMWH) segment is anticipated to witness growth in the forecast period. These anticoagulants have a high efficacy and safety profile. Heparin and low molecular weight heparin are approved for a wide range of indications.

Anticoagulants Market By Route of Administration

The oral anticoagulants segment generated the largest market share in 2025. Oral anticoagulants are convenient, efficacy, and safe compared to traditional anticoagulants. The convenient and easy-to-use nature of oral anticoagulants increases their popularity in the market.

The injectable anticoagulants segment is projected to contribute a significant market share in the forecast period due to its wide range of indications, including in the prevention and treatment of deep vein thrombosis, pulmonary embolism, and acute coronary syndrome. Quick and safe result of injectable anticoagulants drives the demand. 

Anticoagulants Market By Application

The atrial fibrillation/myocardial infarction (heart attack) segment leads the market with the highest market revenue share. The segment growth is attributed to the increased prevalence of stroke and other thromboembolic events in patients with AF. Ongoing R&D efforts to improve the efficacy and safety of anticoagulants are expected to develop advanced strategies for preventing and managing AF and MI in the upcoming period.

The Deep Vein Thrombosis (DVT) segment is anticipated to lead the market in the forecast period with a high prevalence of deep vein thrombosis and demand for drugs that prevent and treat blood clots, like novel oral anticoagulants (NOACs), driven by their high efficacy and safety profile.

Anticoagulants Market By Regional Insights 

North America dominates the global anticoagulants market due to the high prevalence of cardiovascular diseases, aging population, well-established healthcare expenditure, and strong regulatory framework in the region. The presence of key players and high investments in the research and development sector has a significant impact on market expansion. The increased research and development activities, particularly in novel oral anticoagulants (NOACs), provide innovative approaches to anticoagulant drugs.

The United States is leading the regional market. The country has a high prevalence of cardiovascular diseases such as atrial fibrillation, different atrial fibrillation, different thrombosis, and pulmonary embolism. High rate of obesity driving the prevalence of such disease. Additionally, increased spending on healthcare has a positive impact on market expansion.

Asia Pacific is anticipated to witness significant forecast growth. Factors like a rapidly aging population, increased healthcare expenditure, and a large patient population with cardiovascular diseases are driving demands for anticoagulants in the region. Growing awareness about CVDs and the importance of anticoagulation therapy, combined with the presence of strong regulatory frameworks play a crucial role in increasing market expansion. Additionally, the collaborative approaches between research institutes, universities, and pharmaceutical companies contribute to the innovation and development of novel anticoagulant medicines.

• For instance, In April 2025, the group led by Nicolas Winssinger, a professor in the Department of Organic Chemistry at the UNIGE Faculty of Science, collaborated with Richard Payne, a professor at the University of Sydney, to develop a new anticoagulant active ingredient with an "antidote" to reverse its effect rapidly and specifically.

China leading the regional market, driven by a large patient pool and increased healthcare expenditure. China has witnessed high demand for Novel oral anticoagulants (NOACs). The increased focus on cost-effectiveness influences trends and strategies, driving innovation and development. Additionally, government and regulatory initiatives and investments for the R&D sector, to boost the anticoagulant market in the upcoming period.

Some of the prominent players in the Anticoagulants Market include:

• GSK plc
• Boehringer Ingelheim International GmbH
• DAIICHI SANKYO COMPANY, LIMITED
• Sanofi
• Bayer AG
• Aspen Holdings
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services Inc.
• Eisai Co., Ltd.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the Anticoagulants Market

By Drug Category 

• Novel Oral Anticoagulants (NOACs)

• • Eliquis
  • Xarelto
  • Savaysa & Lixiana
  • Pradaxa

• Vitamin K Antagonist
• Direct Thrombin Inhibitors
• Heparin and Low Molecular Weight Heparin (LMWH)
• Others

By Route of Administration 

• Oral Anticoagulants
• Injectable Anticoagulants

By Application 

• Atrial Fibrillation/Myocardial Infarction (Heart Attack)
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism
• Others

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America 
• Middle East & Africa